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Abstract 
Combining computational modeling, de novo compound synthesis and in vitro and 
cellular assays, we have performed an inhibition study against the enhancer of zeste 
homolog 2 (EZH2) histone-lysine N-methyltransferase. This  enzyme is an important 
catalytic component of the PRC2 complex whose alterations have been associated to 
different cancers. We introduce here several tambjamine-inspired derivatives with low 
micromolar in vitro activity that produce a significant decrease in histone 3 tri-
methylation levels in cancer cells. We demonstrate binding at the methyl transfer active 
site, showing, in addition, that the EZH2 isolated crystal structure is capable of being 
used in molecular screening studies. Altogether, this work provides a succesful 
molecular model that will help in the identification of new specific EZH2 inhibitors and 
identify a novel class of tambjamine-derived EZH2 inhibitors with promising activities 
for their use in cancer treatment. 
  
1. Introduction 
Enhancer of zeste homolog 2 (EZH2) is a histone-lysine N-methyltransferase enzyme, 
the catalytic component of the Polycomb Repressive Complex 2 (PRC2) that acts as a 
transcriptional repressor. It catalyzes the addition of three methyl groups, from the S-
adenosyl-L-methionine (SAM) cofactor, to lysine 27 of Histone H3, one of the five 
main histone proteins involved in the structure of chromatin in eukaryotic cells. This 
modification facilitates chromatin compaction and gene silencing of tumor suppressor 
genes in cancer cells1. Since the early observation that EZH2 overexpression was 
associated with progression of prostate cancer2, several EZH2 alterations have been 
associated to other different cancers, including breast, colorectal and lung3-5. Moreover, 
EZH2 overexpression has also been associated with metastasis and poor clinical 
outcome6. Due to these evidences, we find several efforts in developing specific 
inhibitors for EZH2, including various preclinical studies and several human phase 1 
and 2 clinical trials3, 7, 8.  
Such biomedical interest has been translated in recent efforts to obtain crystal 
structures. Since 2013, there is public access to two human EZH2 crystal structures, 
protein data bank (PDB) entries 4MI0 and 4MI5. Since EZH2 without PRC2 
components (SUZ12 and EED) is inactive, there is some controversy about the utility of 
these structures for drug design. In addition, during 2016 several structures of the 
human PRC2 complex were solved, including one with a pyridone inhibitor (pdb entries 
5IJ7, 5IJ8) and a S-adenosyl homocysteine (SAH) cofactor (pdb entry 5HYN, clearly 
indicating the methyl transfer active site)9. Interestingly, these structures reveal an 
unusual binding mode. The inhibitor pocket is formed on the interface of the I-SET 
domain of EZH2, a stretch of 17 residues called by the authors activation loop, and the 
EED protein part of PRC2 complex. Comparing the EZH2/pyridone and the EZH2/SAH 
structures, we can observe that the only overlapping part of the inhibitor with the SAH 
molecule is the pyridone moiety, participating in a similar H-bond networking with 
Trp624.  
We are involved in an anticancer drug discovery program focused at small 
molecules capable of facilitating the transmembrane transport of anions10, some of them 
(which we address here) inspired in the structure of marine secondary metabolites 
tambjamines11. We have synthesized and studied synthetic analogs of these natural 
products, which proved to possess potent anticancer activity in vitro, including activity 
against cancer stem cells12. We are also studying in depth the molecular mechanisms 
responsible for this activity13. A series of these derivatives were submitted to the Target 
Drug Discovery Program, within the Open innovation drug discovery panel, operated by 
Lillya. Preliminary results from this program indicated important activity towards their 
oncology-EZH2 target. Moreover, our cellular assay showed an important reduction of 
histone H3 tri-methylation levels using anti-trimethyl-Histone H3 (Lys27) antibody in 
two selected compounds. These encouraging results prompted us to carry out a study to 
design optimized candidates for this target using computational modeling, to synthesize 
these molecules and to test their in vitro efficacy. 
We report here the results of this broad analysis. Our study indicates for the first 
time that our synthetic tambjamine molecules bind in the methyl transfer active site 
region of the enzyme. These results suggest that the inhibition of EZH2 may be 
involved in the cytotoxic properties of these molecules. Moreover, the knowledge of the 
binding mode, coupled to extensive state-of-the-art induced fit simulations, allowed us 
to design and synthesize 4 new molecules, all presenting low micromolar activity, 
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supporting that the in silico model used is valid for the identification of novel effective 
EZH2 inhibitors.  
 
2. Results and Discussion 
Computational Results 
The exploration of possible binding modes between the studied tambjamine analogs and 
EZH2 started with the standard practice of finding possible binding sites followed by a 
docking procedure. From the apo EZH2 crystal (PDB entry 4MI0), we collected the first 
nine sites identified with SiteMap, which included the SAM catalytic binding site, and 
dock in each of them all the tambjamine analogs (Figure 1). Compounds 1, 2, 3 and 4 
were selected as negative controls (were found negative in the biological assays); 
whereas all other 7 molecules (compounds 5-11) showed experimental low µM inhibitor 
activities against EZH2 in the target drug discovery program performed at Lilly (Table 
1). The complete results of the Glide XP docking scores for the nine discovered binding 
sites are shown in supporting information Table S1. All of them indicate similar (poor) 
scoring values between -3.0 to -6.5 kcal/mol. While absolute docking scores are often 
ligand dependent, low micromolar activities tend to correlate with values < -10 
kcal/mol. Thus, based on the scores obtained from docking, significant inhibition 
activity for EZH2 could not be predicted for the studied compounds. Moreover, there 
seems to be no preferential binding of the ligands into the methyl transfer catalytic site. 
Nevertheless, the negative controls presented overall (slightly) lower scores than the rest 
of molecules, introducing some differentiation between the negative controls 1-4 and 
the other active ligands. 
 
 
 Figure 1. Structure of tambjamine analogs used in the initial docking studies. Negative control 
systems (no detectable inhibition on biological assays) involve molecules 1-4.	  
 
Since standard docking techniques do not sample the receptor conformational changes, 
both at the induced fit or conformational selection level (only a limited ligand flexibility 
is introduced), we turned into PELE for a more robust exploration of the protein-ligand 
energy landscape. In recent studies in mTOR25 and BCL26, for example, we have shown 
the necessity of introducing such type of analysis in order to correlate with experimental 
binding affinities. The first simulation involved a non-biased exploration of the entire 
EZH2 surface (global exploration). In such a procedure, the ligand is placed in the bulk 
solvent and is allowed to explore all the space without any restriction or predefined 
goal. At each PELE Monte Carlo step, the system is perturbed and relaxed, introducing 
significant conformational changes, and the protein-ligand interaction energy is 
computed. The global exploration, aimed at identifying the correct binding site, was 
performed only for compound 8, which introduces an average molecular structure 
among all ligands. Figure 2A shows the nine different ligand starting positions around 
EZH2 (at a distances of ~15 Å from the enzyme’s surface). The 2B panel of the same 
figure shows the results from the exploration (64 processors and 48 hours each) where 
we depict the protein-ligand interaction energies with respect to the (ligand) distance to 
an active site atom: the alpha carbon from Tyr726.  By introducing conformational 
sampling in both the protein and the ligand, we observe now a funnel shaped energy 
landscape towards the methyl transfer active site; this site is now clearly preferred to the 
rest of the protein surface and other cavities.  
 
	  
Figure 2. (A) Different initial positions for tambjamine analog 8 around EZH2 for the non-
biased global PELE exploration. (B) Binding (interaction) energy between compound 8 and 
EZH2 with respect to the distance of the center of mass of 8 and the CG atom from Tyr726 (a 
tyrosine residue located at the SAM binding pocket). 
Following the global exploration, we performed a locally restricted simulation where, 
starting from the best position (lowest interaction energy) obtained in the global search, 
we limited the ligand to explore only the vicinity of the active site.  Here, we expanded 
a local sampling for all the ligands shown in Figure 1, where we manually edited the 
changes in chemical substituents with Maestro. As an additional positive control, we 
also performed the local exploration for the SAH co-factor, using again the apo EZH2 
crystal, and compared the best interaction energy to the recent human PRC2 complex 
crystal (PDB entry 5HYN), including a SAH cofactor. Figure 3 shows an excellent level 
of agreement between our model and the crystal, where we reproduce the overall 
position and main interactions. 
 
Figure 3. SAH co-factor binding comparison between the PELE simulation using the EZH2 apo 
structure (pdb entry 4MI0, panel A) and the recent human PCR2 complex (pdb entry 5HYN, 
panel B). Panel C shows our model and the crystal overlapped.	  
 From the local sampling we extracted the best 10 structures (with lowest interaction 
energy) for each compound and performed additional scoring calculations with Glide. 
Thus, we were able to compare the protein-ligand affinity score before and after the 
induced fit process. The results clearly indicate a significant improvement in the ligands 
scores, reaching now values in agreement to their level of activity (~ -10 kcal/mol) 
(Table 1). Importantly, all the negative controls still show significant lower values than 
the active ligands. The binding mode shows the ability of the molecule to enter in the 
“end” of the channel where Lys27, the histone’s lysine, is methylated. We should 
emphasize here that this channel is collapsed in the original apo crystal, which severely 
restricts the model to be used in standard docking calculations, thus requiring induced 
fit techniques.  
Compound Initial 
docking 
PELE + 
docking 
IC50 
(µM) 
1 -3.7 -7.3 (-6.5) - 
2 -3.9 -8.0 (-7.3) - 
3 -3.7 -5.8 (-5.3) - 
4 -4.0 -8.1 (-7.6) - 
5 -4.6 -10.5 11.7 
6 -4.3 -10.4 8.4 
7 -5.1 -9.4 11.0 
8 -5.2 -10.5 12.9 
9 -4.2 -9.7 8.7 
10 -4.6 -9.3 23.5 
11 -4.7 -9.3 26.9 
Table 1. Average docking scores (in kcal/mol) before and after PELE and experimental 
affinities obtained from the target drug discovery program performed at Lilly (half inhibitory 
concentrations (IC50)). Negative control ligands (in grey background color) show both the 
protonated and deprotonated (in parenthesis) docking scores. 
 
The flexibility of the binding pocket and ligands produced several binding modes of 
similar (low) interaction energies. Nevertheless, in most of the best (lowest energy) 
poses, the more flexible moiety of the ligand occupies the hydrophobic pocket around 
Leu666, at the I-SET domain (Figure 4) observed by Hong Wu et al. 27, directly 
distressing the cognate substrate binding. In addition, the characteristic methoxy group 
of these derivatives binds approximately at the methyl transfer area of EZH2, as 
observed when comparing our models with the recent 5HYN crystallographic structure. 
As seen in Figure 4, the indole moiety participates in a hydrogen bond with Asn688, 
mimicking the role observed for the SAH co-factor. Moreover, recently deposited PDB 
entries 5T5G and 5TH7 of the SETD8 protein (with a catalytic pocket structurally 
similar to EZH2) showed methoxy group containing inhibitors whose positions overlap 
well with that of our tambjamine analogs methoxy group. All these results underscore 
the ability of these derivatives inhibiting the methyl transfer from SAM to Lys27. 
All active compounds bear a positive charge, which seems to benefits from binding in 
the methyl transfer cavity, which has evolved to accommodate the positively charged 
histone’s lysine and SAM cofactor. The increase in the binding score for the protonated 
form of control ligands (with respect to their deprotonated forms) seems to confirm this 
point. Nevertheless, the increase is moderate and we still observe a clear difference 
between active and inactive compounds, indicating that additional aspects, such as the 
imine substituent flexibility, are necessary to accommodate the molecule in the catalytic 
pocket.  
 
 
Figure 4. (A) Induced fit docking derived structure for tambjamine 5 (important residues and I-
SET domain marked in blue). (B) Ligand 2D interaction diagram for tambjamine 5 with H-
bonds underlined in purple, π- π interactions in green and π-cation ones in red. 
 
The molecular knowledge of the binding mode was further challenged by designing a 
second generation set of inhibitors. Based on the above local exploration, eight different 
snapshots were selected for molecular docking. A small library varying the imine 
substituent of the tambjamine analogs was created. The library contained 150 fragments 
selected by molecular complementarity based on the docking grid (available volume). A 
further selection of 19 molecules was done based on their docking scores (< 11) (see 
Figure S2 for details) and from this set of candidates four of them were successfully 
synthesized to experimentally test the validity of our calculations (compounds 12-15, 
Figure 5). The four molecules were tested again in the OIDD Lilly assay and all of them 
were found to be positive hits, displaying activities in the low micromolar range (Table 
2). The fact that all the designed molecules were found active even when significant 
structural changes were introduced (at the hydrogen bond acceptor/donor level), 
underscore the capabilities of the molecular model and overall procedure. Although the 
IC50 values obtained did not improve those found in the first generation of molecules, 
the scaffold is useful for the identification of EZH2 inhibitors and further studies with 
more diverse compounds should be performed. In addition, the lack of improvement 
might be due to the limited precision of docking scores; more elaborate free energy 
methods might be better suited to guide lead optimization efforts. 
 
Figure 5. Second generation of synthesized tambjamine analogs after computational directed 
design.  
 
Compound Docking IC50 
(µM) 
12 -11.9 12.56 
13 -11.4 11.77 
14 -11.8 36.3 
15 -11.8 15.81 
Table 2. Docking scores (in kcal/mol) and experimental affinities for the second generation 
ligand molecules. 
 
Cell assays 
EZH2 is a well-established therapeutic target for several cancers, so we wanted to 
analyze whether our tambjamine-inspired molecules are potential chemotherapeutic 
compounds. Thus, in order to complement and validate the in vitro enzymatic assay, we 
selected two compounds and their activity in cancer cells was assessed. Lung 
adenocarcinoma A549 cells were treated with 2 µM of compound 5 and compound 6 for 
96 h and tri-methylation levels in Lys27 of histone 3 were assessed by 
immunofluorescence. As observed in Figure 6, both compounds induced a very 
significant decrease in histone 3 tri-methylation levels in cells. After fluorescence 
intensity quantification and normalization, cells treated with tambjamine analogs 5 and 
6 showed a relative fluorescence (in percentage) of 11.37 ± 8.5 and 12.03 ± 6.5 
respectively, compared to non-treated cells. These results indicate a statistically 
significant effect and corroborate in cancer cells the potent EZH2 inhibition by these 
compounds, formerly detected in in vitro experiments (Figure 7). Therefore, these 
compounds effectively inhibit the cancer therapeutic target EZH2, suggesting that they 
may be good candidate agents for the treatment of different cancers.     
 
 Figure 6. Histone H3 Lys 27 tri-methylation levels. A549 cells were treated with 2 µM of 
each compound (compounds 5 and 6)  or with 1% DMSO (CT, control cells) for 96 h and 
immunostaining was performed using anti-trimethyl-Histone H3 (Lys27) antibody. Results 
shown are representative images of three immunostaining experiments. 
  
Figure 7. Histone H3 Lys 27 tri-methylation quantification. Histone H3 tri-methylation 
fluorescence was quantified in treated (compounds 5 and 6) or non-treated (CT) A549 cells; 
average normalized intensities are shown (percentage). Statistical significance was assessed by 
One-way ANOVA with post-hoc Tukey HSD test (**, p value<0.01). 
 
3. Conclusion 
Molecular modeling together with in vitro and cell assays indicate the capabilities of 
several tambjamine-inspired derivatives to inhibit EZH2, an important catalytic 
component of the PRC2 complex whose alterations have been associated to different 
cancers. These molecules are predicted to bind in the methyl transfer active site, which 
has evolved to accommodate the positively charged histone’s lysine and SAM cofactor. 
In agreement with this, the most active compounds present a positive charge, although 
our simulations indicate that introducing a positive charge in the control (neutral) 
ligands only slightly improve the docking scores; a flexible hydrophobic group is 
necessary for an effective inhibition of the catalytic pocket. While we show here that the 
EZH2 isolated apo crystal is capable of being used in molecular modeling studies, these 
require an important level of conformational sampling. These results represents another 
(yet) example of how rigid docking studies are not capable of predicting potency 
(screening capabilities) nor the correct binding pose (lead optimization capabilities), 
being necessary to carry on conformational landscape exploration simulations, such as 
PELE. 
EZH2 role in tumorigenesis has been widely validated in many different tumors, being a 
relevant therapeutic target for the treatment of this malignancy28. Many pre-clinical data 
support that EZH2 inhibitors effectively block the growth of cancer cells from different 
tumors, and preliminary clinical results with the most advanced EZH2 inhibitor EPZ-
6438 (Tazemetostat) have shown durable tumor responses, especially in patients with 
B-cell lymphomas3. Altogether, these data suggest that synthetic tambjamine analogs 
may be promising novel EZH2 inhibitors for cancer treatment. 
 
4. Material and Methods 
Computational Methods	  
System preparation and docking. The crystal structure, PDBID 4MI0, was optimized 
with the protein preparation wizard tool from Schrodinger.14 The protonation state of 
titrable residues were assigned at physiological pH with PROPKA and double-checked 
with the H++ server.15 Eleven tambjamine analogs, including four negative controls 
(molecules 1-4), were studied in the initial docking calculations (Figure 1). Selected 
tambjamines were optimized with the LigPrep default protocol, which indicated the 
ambiguous protonation nature of all control ligands, the remaining molecules showing a 
positive charge at physiological pH.  Charge assignments were confirmed with 
additional pKa calculations at the B3LYP and 6-31G (d, p) basis set level of quantum 
chemistry theory by using Jaguar.16 All negative controls gave a pKa range between 5-
7, possibly due to the delocalization of electron density into the aromatic substituent, 
while the rest of the systems presented pKa values >8. Thus, the negative controls were 
prepared in a protonated and deprotonated forms. Schrodinger ConfGen tool was then 
used to generate possible conformations for the tambjamines, and their electrostatic 
potential charges extracted from the Jaguar calculations described above. SiteMap17 was 
then used for selecting probable docking sites and nine grids were calculated and a 
library of possible tambjamines conformations was docked to all nine sites. Docking 
was performed with Glide, using the XP scoring function.18 
Induced fit simulations. PELE,19 our in-house software combining a Monte Carlo 
(MC) stochastic approach with protein structure prediction algorithms, was used to 
refine the initial docking poses. PELE is capable of accurately reproducing long-
timescale processes in a 1–2 order of magnitude faster manner than molecular 
dynamics. It has been underlined, for example, as one of the most promising techniques 
in the latest CSAR blind docking competition20. When compared to docking techniques, 
it provides a good induced fit description, allowing the docking in difficult cases (apo, 
cross docking, etc.)21. Briefly, the sampling algorithm is based on a consecutive 
iteration of three main steps: a ligand and protein (backbone) perturbation, a side-chain 
sampling, and a minimization.19 Thus, the procedure begins by a ligand perturbation 
involving a random translation and rotation of the ligand. In the case of the protein, the 
perturbation is based on the α-carbons anisotropic network model22. Following the 
perturbation, a relaxation step is introduced, involving a side chain prediction for all 
residues with 6 Å from the ligand and an overall minimization. These steps compose a 
move that is accepted (defining a new local minimum) or rejected based on a 
Metropolis criterion, forming a stochastic trajectory. PELE uses an OPLS (Optimized 
Potentials for Liquid Simulations) all-atom force field23 with an implicit surface-
generalized Born continuum solvent model 24. 
Two different types of PELE simulations were performed: a global and a local 
sampling. Global sampling, using large ligand translations (up to 5Å) and rotations (up 
to 90°) without any restriction of the space explored, aims at finding ligand binding 
sites. Nine different positions, with the ligand in the protein surface, were used as the 
initial protein-ligand structures (Figure 2). To enhance the exploration, the ligand 
perturbation random search direction is also kept for 3 steps. In order to map possible 
conformational selection on the receptor we used larger backbone perturbations, with 
~1Å alpha carbon displacements in each MC step, where we keep the normal mode for 
6 consecutive steps. The global exploration used 64 processors and 48 hours each, 
giving a total of approximately 70,000 MC new minima that explored the entire surface 
(and inner cavities). 
The local sampling focuses the sampling in one region by reducing considerably the 
ligand translation (up to 1.5 Å), and by keeping the ligand’s perturbation direction for 
only one step. The backbone perturbation direction is also reduced to 1 step. The 
sampling was performed using 12 processors and 12 hours, producing approximately 
500-1000 MC minima (notice that, due to steric clashes, the acceptance in local 
sampling is reduced from that of global sampling). Disregarding duplicates (RMSD < 
0.2 Å), the average ligand heavy atom RMSD along the different posses obtained is 
significantly large, ~2.5 Å. Thus the local sampling effectively maps the different 
conformations adopted by the ligands in an active site. 
Experimental Methods 
EZH2 SPA Enzymatic Assay. Human EZH2 was co-expressed as a 5-member 
enzymatic complex with SUZ12, EED, AEBP2 and RbAp48 using a baculovirus/Sf9 
insect cell system. The EZH2 complex was purified using FLAG affinity 
chromatography.  A biotinylated peptide corresponding to human Histone 3 (H3) 
residues 21-44 was used as the substrate (CPC Scientific Inc., San Jose, CA, Cat# 
811115).  A peptide corresponding to H3 residues 21-44 that was trimethylated on 
Lys27 was used as a coactivating factor (CPC Scientific Cat # 869799).  Adenosyl-L-
methionine,S-(methyl)-3H (Adomet) (15 Ci/mmol or 0.55 mCi/ml) was used as the 
radiolabelled tracer (Perkin Elmer NET155).  Streptavidin-coated yttrium silicate SPA 
beads were used to capture and quantify substrate labelled with tritiated methyl groups 
(Perkin Elmer Cat# RPNQ0012).  Working solutions of any of the above reagents were 
diluted in Assay buffer (50 mM Tris-HCl pH 8.5, 10 mM DTT, 0.005% Triton X-100). 
Compounds were serially diluted 3-fold (100% DMSO) for initial top concentrations of 
either 1 or 100 uM.  The reaction was assembled at room temp in a 384-well white clear 
bottom assay plate (Corning, NY, USA, Cat# 3706); 15 µL of a premixed solution of 
EZH2 5 mER/trimethylated coactivator peptide; 100-200 nL of serially-diluted 
compound; 5 µL of a premixed solution of 3H-Adomet/peptide substrate to yield final 
reaction conditions of 2.5 nM EZH2, 10 nM trimethyl coactivator peptide, 1 µM 3H-
Adomet and 1 µM peptide substrate.  The plate was sealed and shaken for 2 hours at 
room temperature (RT).  Streptavidin-coated yttrium silicate SPA beads were 
reconstituted at 1mg/mL in 3 M Guanidine HCL and briefly sonicated prior to a 20 µL 
dispense in the assay plate (20 µg beads per well) to stop the reaction.  The plates were 
sealed and then shaken for 10 minutes.  The beads were then allowed to settle for 60 
minutes prior to counting on a Microbeta Trilux (Perkin Elmer).   
Immunofluorescence staining. A549 cells (8x104 cells/mL) were cultured in a 12-well 
plate containing FBS-coated glass coverslips. After 24 h, they were incubated 96 h with 
2 µM of two of the studied compounds (5 and 6, as shown in Figure 1). Cells were then 
washed twice with PBS and fixed with PBS-2% paraformaldehyde for 10 min at RT. 
Fixed cells were washed twice with PBS and permeabilized with PBS-0.1% Triton X-
100 during 10 min. They were then washed twice with washing solution (WS, PBS-
0.1% Tween 20) for 5 min and treated 30 min at RT with blocking solution (PBS-
Tween-20 0.1%, 0.1% Bovine Serum Albumin and 10% normal goat serum). Cells were 
incubated overnight at 4ºC with primary antibody (1:500, Anti-trimethyl-Histone H3 
(Lys27) Antibody, EMD Millipore Corporation, Billerica, MA, USA) diluted in 
blocking solution. Cells were then washed with WS three times and incubated with 
Alexa Fluor 488-conjugated donkey anti rabbit (Molecular Probes, Invitrogen, 
Carlsbad, CA, USA) at 1:400 dilution for 1 h at RT. Afterwards, coverslips were 
washed with WS and placed on the slides with Mowiol (Sigma-Aldrich, St. Louis, MO, 
USA). Images were captured using a Leica TCS-SL filter-free spectral confocal 
microscope (Leica Microsystems, Wetzlar, Germany). Three independent experiments 
were performed and fluorescence intensities (n=30/condition) were normalized and 
quantified by Image J software. Statistical analysis was performed with Statgraphics 
Centurion XVI software (Manugistics, Rockville, MD, USA) using One-way ANOVA 
with post-hoc Tukey HSD test. 
General procedures. Purchased reagents were used as received without any further 
purification. The 1H and 13C NMR spectra were recorded on Varian Mercury-300 MHz 
and Varian Unity Inova-400 MHz spectrometers, using CDCl3 or DMSO-d6 as solvents. 
Chemical shifts are reported as δ values in parts per million (ppm) using the residual 
solvent peak as a reference and coupling constants are reported in Hz. Data are reported 
as follows: chemical shift, multiplicity (splitting pattern abbreviations are: s: singlet, d: 
doublet, dd: doublet of doublets, dt: doublet of triplets, t: triplet, td: triplet of doublets, 
q: quartet, m: multiplet, app t: apparent triplet, app q: apparent quartet). Mass spectra 
(HRMS) were obtained with a Micromass Autospec S-2 spectrometer using EI at 70 eV.  
Synthesis of compounds (1-15). 4-methoxy-1H,1'H-[2,2'-bipyrrole]-5-carbaldehyde 
was synthesized as described.29 This set of compounds was synthetized applying 
modifications to a previously reported method.30 Briefly, the corresponding amine (1.7–
4 equivalents) was added, at room temperature, over a suspension of the carboxaldehyde 
in chloroform (80–100 mM aldehyde) or 1,2-dichloroethane (for 2, 3, 7 and 15). Then, 
acetic acid (40–400 µL) was added. The reaction mixture was stirred under reflux 
overnight or until TLC (hexane:AcOEt 1:1) analysis indicated complete consumption of 
the starting material. The mixture was then cooled to room temperature. It was washed 
three times (x 30 mL) with HCl 1M. The organic phase was dried on Na2SO4 and the 
solvent was removed under vacuum to yield the desired products, as yellow-orange 
solids in good yields. In the case of compound 14 the work up is slightly different. The 
organic layer was washed with a buffer solution (20 mM NaH2PO4 pH 7.2, ionic 
strength 1 M NaCl). Compounds 5, 6, were previously reported by us.12 See Supporting 
information for a reaction scheme and the NMR and HRMS spectra of each compound. 
The full list of logP and LLE (pIC50 – logD) values for all compounds is provided in 
Supporting Information.  
N-((5-(1H-indol-2-yl)-3-methoxy-1H-pyrrol-2-yl)methylene)-4-(tert-
butyl)benzenaminium chloride (1.HCl). Yield: 59%. 1H NMR (300 MHz, CDCl3) δ = 
13.56 (s, 1H), 11.48 (d, J = 12.8 Hz, 1H), 10.19 (s, 1H), 7.40–7.28 (m, 5H), 7.22–7.13 
(m, 3H), 6.97 (t, J = 7.5 Hz, 1H), 6.92 (s, 1H), 6.03 (s, 1H), 3.75 (s, 3H, OCH3), 1.29 (s, 
9H). 13C NMR (75 MHz, CDCl3) δ = 164.33 (C), 149.68 (C), 142.53 (C), 138.04 (C), 
135.58 (C), 131.66 (CH), 127.88 (C), 127.32 (C), 126.67 (2CH), 125.01 (CH), 121.46 
(CH), 120.71 (CH), 117.12 (2CH), 113.22 (C), 112.09 (CH), 107.11 (CH), 93.49 (CH), 
58.74 (OCH3), 34.63 (C), 31.30 (3CH3). ). HRMS (EI) m/z calc for [C24H25N3O] 
371.1998; found 371.2000. 
N-((5-(1H-indol-2-yl)-3-methoxy-1H-pyrrol-2-yl) methylene)-4-
methoxybenzenaminium chloride (2.HCl). Yield: 95%. 1H NMR (300 MHz, DMSO-
d6) δ = 13.52 (s, 1H), 13.09 (d, J = 14.3 Hz, 1H), 12.00 (s, 1H), 8.41 (d, J = 14.0 Hz, 
1H), 7.74–7.59 (m, 3H), 7.52–7.42  (m, 2H), 7.24 (t, J = 7.6 Hz, 1H), 7.15–7.00 (m, 
3H), 6.77 (s, 1H), 4.03 (s, 3H, OCH3), 3.78 (s, 3H, OCH3). 13C NMR (75 MHz, DMSO-
d6) δ = 164.04 (C), 157.92 (C), 141.03 (C), 137.92 (C), 134.84, (CH), 131.49 (C), 
127.79 (C), 124.12 (CH), 121.27 (CH), 120.50 (CH), 119.47 (2CH), 114.98 (2CH, C), 
112.83 (C), 111.84 (CH), 103.73 (CH), 94.06 (CH), 58.87 (OCH3), 55.50 (OCH3). 
HRMS (EI) m/z calc for [C21H19N3O2] 345.1477; found: 345.1469. 
N-((5-(1-(tert-butoxycarbonyl)-1H-indol-2-yl)-3-methoxy-1H-pyrrol-2-
yl)methylene)-4-methoxybenzenaminium chloride (3.HCl). Yield: 64%. 1H NMR 
(300 MHz, CDCl3) δ = 13.73 (d, J = 13.7 Hz, 1H), 13.45 (s, 1H), 8.08 (d, J = 8.4 Hz, 
1H), 7.96 (d, J = 14.8 Hz, 1H), 7.65 (d, J = 7.4 Hz, 1H), 7.54–7.48  (m, 2H), 7.42 (s, 
1H), 7.37 (d, J = 7.3 Hz, 1H), 7.27 (t, J = 7.5, 1H), 7.00–6.90 (m, 2H), 6.06 (d, J = 1.8, 
1H), 3.97 (s, 3H, OCH3), 3.82 (s, 3H, OCH3), 1.63 (s, 9H, 3 CH3). 13C NMR (75 MHz, 
CDCl3) δ = 162.94 (C), 158.80 (C), 149.86 (C), 142.36 (C), 138.51 (C), 134.37 (CH), 
131.77 (C), 129.56 (C), 128.83 (C), 126.63 (CH), 123.74 (CH), 122.35 (CH), 119.76 
(2CH), 115.95 (CH), 115.72 (CH), 115.21 (2CH), 112.61 (C), 97.17 (CH), 85.12 (C), 
58.66 (OCH3), 55.76 (OCH3), 28.25 (3CH3). HRMS (EI) m/z calc for [C26H27N3O4] 
445.2002; found: 445.2011. 
(E)-N-((5-(1H-indol-2-yl)-3-methoxy-1H-pyrrol-2-yl)methylene)benzenaminium 
chloride (4.HCl). Yield: 53%. 1H NMR (300 MHz, CDCl3) δ = 13.87 (s, 1H), 11.63 (s, 
1H), 10.31 (s, 1H), 7.57 (s, 1H), 7.49 (d, J = 3.0 Hz, 1H), 7.46 (d, J = 2.7 Hz, 1H), 
7.41–7.35 (m, 4H), 7.28–7.18 (m, 2H), 7.10–7.00 (m, 2H), 6.15 (s, 1H), 3.91 (s, 3H, 
OCH3). 13C NMR (75 MHz, CDCl3) δ = 164.89 (C), 143.54 (C), 138.39 (C), 138.28 (C), 
131.84 (CH), 130.02 (2CH), 128.03 (C), 127.35 (C), 126.47 (CH), 125.46 (CH), 121.63 
(CH), 121.00 (CH), 117.55 (2CH), 113.74 (C), 112.46 (CH), 107.74 (CH), 93.63 (CH), 
58.95 (OCH3). HRMS (EI) m/z calc for [C20H17N3O] 315.1363; found: 316.1447. 
N-((5-(1H-indol-2-yl)-3-methoxy-1H-pyrrol-2-yl)methylene) dodecan-1-aminium 
acetate (7.HOAc). Yield: 38%. 1H NMR (300 MHz, CDCl3) δ = 12.21 (s, 1H), 7.59 (d, 
J = 8.0 Hz, 1H), 7.52 (dd, J = 8.2, 0.8 Hz, 1H), 7.41 (s, 1H), 7.27–7.21 (m, 1H), 7.12–
7.04 (m, 1H), 6.94 (d, J = 1.1 Hz, 1H), 6.15 (s, 1H), 3.90 (s, 3H, OCH3), 3.46 (app t, J = 
7.1 Hz, 2H), 2.13 (s, 3H. CH3CO2-), 1.77–1.66 (m, 2H), 1.35–1.21 (m, 18H), 0.87 (t, J = 
6.7 Hz, 3H). 13C NMR (75 MHz, CDCl3) δ = 178.34 (C, CH3CO2-), 163.09 (C), 142.53 
(CH), 141.90 (C), 138.40 (C), 128.61 (C), 128.14 (C), 124.01 (CH), 120.96 (CH), 
120.29 (CH), 112.44 (CH), 111.63 (C), 105.09 (CH), 92.82 (CH), 58.38 (OCH3), 51.54 
(CH2), 32.03 (CH2), 30.46 (CH2), 29.74 (2CH2), 29.69 (CH2), 29.60 (CH2), 29.47 
(CH2), 29.29 (CH2), 26.65 (CH2), 23.87 (CH3, CH3CO2-), 22.81 (CH2), 14.25 (CH3). 
HRMS (EI) m/z calc for [C26H37N3O] 407.2937; found: 407.2953. 
N-((5-(1H-indol-2-yl)-3-methoxy-1H-pyrrol-2-yl)methylene)-3-methylbutan-1-
aminium chloride (8.HCl). Yield: 90%. 1H NMR (300 MHz, CDCl3) δ = 13.89 (s, 1H), 
10.32 (s, 1H), 10.02 (d, J = 14.8 Hz, 1H), 7.59 (d, J = 8.0 Hz, 1H), 7.52 (d, J = 8.3 Hz, 
1H), 7.36 (d, J = 15.2 Hz, 1H), 7.26 (t, J = 7.7 Hz, 1H), 7.10 (t, J = 7.5 Hz, 1H), 7.01 (d, 
J = 2.0 Hz, 1H), 6.14 (d, J = 2.3 Hz, 1H), 3.90 (s, 3H, OCH3), 3.52 (app q, 2H), 1.79–
1.63 (m, 3H), 0.96 (d, J = 6.3 Hz, 6H). 13C NMR (75 MHz, CDCl3) δ = 163.30 (C), 
142.05 (CH), 141.31 (C), 138.03 (C), 128.05 (C), 127.80 (C), 124.88 (CH), 121.29 
(CH), 120.81 (CH), 112.45 (CH), 111.45 (C), 106.03 (CH), 92.69 (CH), 58.66 (OCH3), 
49.65 (CH2), 38.88 (CH2), 25.59 (CH), 22.40 (2CH3). HRMS (EI) m/z calc for 
[C19H23N3O] 309.1841; found: 309.1850. 
N-((5-(1H-indol-2-yl)-3-methoxy-1H-pyrrol-2-yl)methylene)octan -1-aminium 
chloride (9.HCl). Yield 98%. 1H NMR (300 MHz, CDCl3) δ = 13.44 (s, 1H), 10.36 (s, 
1H), 9.93 (d, J = 14.3 Hz, 1H), 7.52 (d, J = 7.9 Hz, 1H), 7.45 (d, J = 8.1 Hz, 1H), 7.23–
7.09 (m, 2H), 7.04 (t, J = 7.5 Hz, 1H), 6.98 (s, 1H), 6.11 (s, 1H), 3.72 (s, 3H, OCH3), 
3.36 (app q, 2H), 1.75–1.60 (m, 2H), 1.36–1.16 (m, 10H), 0.83 (t, J = 6.5 Hz, 3H). 13C 
NMR (75 MHz, CDCl3) δ = 163.09 (C), 141.84 (CH), 140.71 (C), 137.72 (C), 127.90 
(C), 127.65 (C), 124.37 (CH), 121.11 (CH), 120.49 (CH), 112.00 (CH), 111.04 (C), 
105.47 (CH), 92.74 (CH), 58.41 (OCH3), 51.14 (CH2), 31.68 (CH2), 29.99 (CH2), 29.04 
(CH2), 29.00 (CH2), 26.44 (CH2), 22.55 (CH2), 14.05 (CH3). HRMS (EI) m/z calc for 
[C22H29N3O] 351.2311; found: 351.2306. 
N-((5-(1H-indol-2-yl)-3-methoxy-1H-pyrrol-2-yl)methylene)-4-
butylbenzenaminium chloride (10.HCl). Yield: 89%. 1H NMR (300 MHz, CDCl3) δ = 
13.46 (s, 1H), 10.35 (s, 1H), 9.93 (d, J = 14.8 Hz, 1H), 7.52 (d, J = 7.9 Hz, 1H), 7.45 (d, 
J = 8.2 Hz, 1H), 7.22–7.10 (m, 2H), 7.04 (t, J = 7.5 Hz, 1H), 6.98 (s, 1H), 6.11 (s, 1H), 
3.73 (s, 3H, OCH3), 3.38 (app q, 2H), 1.74–1.59 (m, 2H), 1.45–1.30 (m, 2H), 0.90 (t, J 
= 7.3 Hz, 3H). 13C NMR (75 MHz, CDCl3) δ = 163.07 (C), 141.85 (CH), 140.67 (C), 
137.67 (C), 127.86 (C), 127.61 (C), 124.30 (CH), 121.09 (CH), 120.44 (CH), 111.91 
(CH), 110.99 (C), 105.39 (CH), 92.73 (CH), 58.35 (OCH3), 50.78 (CH2), 31.86 (CH2), 
19.60 (CH2), 13.46 (CH3). HRMS (EI) m/z calc for [C18H21N3O] 295.1685; found: 
295.1683. 
N-((5-(1H-indol-2-yl)-3-methoxy-1H-pyrrol-2-yl)methylene)-2-methylpropan-1-
aminium chloride (11.HCl). Yield: 43%. 1H NMR (300 MHz, CDCl3) δ = 13.85 (s, 
1H), 10.36 (s, 1H), 9.97 (d, J = 14.8 Hz, 1H), 7.58 (d, J = 8.0 Hz, 1H), 7.51 (dd, J = 8.3, 
0.8, 1H), 7.32–7.21 (m, 2H), 7.12–7.09 (J = 8.0 Hz, 1H), 7.01 (d, J = 1.3 Hz, 1H), 6.14 
(d, J = 2.2 Hz, 1H), 3.87 (s, 3H, OCH3), 3.29 (app t, 2H), 2.10–1.97 (m, 1H), 1.03 (d, J 
= 6.7 Hz, 6H). 13C NMR (75 MHz, CDCl3) δ = 163.44 (C), 142.43 (CH), 141.34 (C), 
137.99 (C), 128.02 (C), 127.76 (C), 124.80 (CH), 121.28 (CH), 120.75 (CH), 112.38 
(CH), 111.28 (C), 106.02 (CH), 92.75 (CH), 59.00 (CH2), 58.64 (OCH3), 29.55 (CH), 
19.94 (2CH3). HRMS (EI) m/z calc for [C18H21N3O] 295.1685; found: 295.1685. 
N-((5-(1H-indol-2-yl)-3-methoxy-1H-pyrrol-2-yl)methylene)-2-(4-
ethylphenyl)ethanaminium chloride (12.HCl). Yield: 93%. 1H NMR (300 MHz, 
CDCl3) δ = 13.94 (s, 1H), 10.31 (s, 1H), 10.16 (d, J = 14.5 Hz, 1H), 7.60 (d, J = 8.1 Hz, 
1H), 7.55 (dd, J = 8.3, 0.8 Hz, 1H), 7.32–7.24 (m, 1H), 7.20–7.09 (m, 6H), 7.01 (dd, J = 
2.1, 0.8 Hz, 1H), 6.13 (d, J = 2.3 Hz, 1H), 3.89 (s, 3H, OCH3), 3.74 (app q, 2H), 3.07 (t, 
J = 7.2 Hz, 2H), 2.62 (q, J = 7.6 Hz, 2H), 1.21 (t, J = 7.6 Hz, 3H). 13C NMR (75 MHz, 
CDCl3) δ= 163.49 (C), 143.19 (C), 142.14 (CH), 141.51 (C), 138.07 (C), 134.18 (C), 
129.09 (2CH), 128.46 (2CH), 128.06 (C), 127.73 (C), 124.93 (CH), 121.32 (CH), 
120.84 (CH), 112.47 (CH), 111.42 (C), 106.19 (CH), 92.74 (CH),  58.62 (OCH3), 52.82 
(CH2), 36.12 (CH2), 28.59 (CH2), 15.74 (CH3). HRMS (EI) m/z calc for [C24H25N3O] 
371.1998; found: 371.2003. 
N-((5-(1H-indol-2-yl)-3-methoxy-1H-pyrrol-2-yl)methylene)-2-(3-chloro-4-
fluorophenyl)ethanaminium chloride (13.HCl). Yield: 80%. 1H NMR (300 MHz, 
DMSO-d6) δ = 13.27 (s, 1H), 11.92 (s, 1H), 11.27 (s, 1H), 8.12 (d, J = 12.9 Hz, 1H), 
7.64 (d, J = 7.9 Hz, 1H), 7.53 (t, J = 8.1 Hz, 1H), 7.48–7.42 (m, 2H), 7.43 (s, 1H), 7.26–
7.18 (m, 2H), 7.08 (app t, J = 7.5 Hz, 1H), 6.69 (s, 1H), 3.96 (s, 3H, OCH3), 3.91 (s, 
2H), 3.02 (t, J = 6.7 Hz, 2H). 13C NMR (75 MHz, DMSO-d6) δ = 162.79 (C), 157.07 (d, 
JC-F = 244.5 Hz, C), 145.24 (CH), 139.67 (d, JC-F = 6.7 Hz, C), 139.41 (C), 137.65 (C), 
130.52 (CH), 127.99 (C), 127.76 (C), 126.51 (d, JC-F = 3.2 Hz, CH) 123.80 (CH), 
121.12 (CH), 120.38 (CH), 117.56 (d, JC-F = 17.25 Hz, C), 117.45 (d, JC-F = 20.25 Hz, 
CH), 111.75 (CH), 110.79 (C), 102.80 (CH), 93.52 (CH), 58.68 (OCH3), 50.49 (CH2), 
34.48 (CH2). HRMS (EI) m/z calc for [C22H19ClFN3O] 395.1201; found: 395.1190. 
N-((5-(1H-indol-2-yl)-3-methoxy-1H-pyrrol-2-yl)methylene)-2-(pyridin-4-
yl)ethanaminium chloride (14.HCl). Yield: 73%. 1H NMR (300 MHz, DMSO-d6) δ = 
13.36 (s, 1H), 11.96 (s, 1H), 11.42 (s, 1H), 8.59–8.46 (m, 2H), 8.11 (s, 1H), 7.64 (d, J = 
7.9 Hz, 1H), 7.45 (d, J = 8.2 Hz, 1H), 7.38–7.32 (m, 3H), 7.22 (t, J = 7.6 Hz, 1H), 7.08 
(t, J = 7.5 Hz, 1H), 6.70 (s, 1H), 4.01–3.89 (m, 5H), 3.03 (t, J = 7.0 Hz, 2H). 13C NMR 
(75 MHz, DMSO-d6) δ = 162.70 (C), 149.63 (2CH), 146.75 (C), 145.16 (CH), 139.33 
(C), 137.63 (C), 128.03 (C), 127.76 (C), 124.43 (2CH), 123.75 (CH), 121.09 (CH), 
120.35 (CH), 111.74 (CH), 110.85 (C), 102.81 (CH), 93.54 (CH), 58.66 (OCH3), 49.95 
(CH2), 34.44 (CH2). HRMS (EI) m/z calc for [C21H20N4O] 344.1637; found: 344.1644. 
N-((5-(1H-indol-2-yl)-3-methoxy-1H-pyrrol-2-yl)methylene)-2-(4-hydroxy-3,5-
dimethylphenyl)ethanaminium chloride (15.HCl). Yield: 41%. 1H NMR (300 MHz, 
DMSO-d6) δ = 13.21 (s, 1H), 11.90 (s, 1H), 11.22 (d, J = 14.9 Hz, 1H), 8.13–8.03 (m, 
2H), 7.65 (d, J = 7.9 Hz, 1H), 7.45 (d, J = 8.2 Hz, 1H), 7.32 (s, 1H), 7.22 (t, J = 7.6 Hz, 
1H), 7.08 (t, J = 7.6 Hz, 1H), 6.84 (s, 2H), 6.69 (d, J = 2.1 Hz, 1H), 3.96 (s, 3H, OCH3), 
3.80 (app q, 2H), 2.81 (t, J = 7.0 Hz, 2H), 2.11 (s, 6H). 13C NMR (75 MHz, DMSO-d6) 
δ = 162.55 (C), 151.79 (C), 145.17 (CH), 139.06 (C), 137.61 (C), 128.71 (2CH), 128.08 
(C), 127.77 (C), 127.75 (C), 124.18 (2C), 123.71 (CH), 121.07 (CH), 120.34 (CH), 
111.72 (CH), 110.71 (C), 102.65 (CH), 93.46 (CH), 58.64 (OCH3), 51.42 (CH2), 34.75 
(CH2), 16.61 (2CH3). HRMS (EI) m/z calc for [C24H25N3O2] 387.1947; found: 
387.1931. 
5. Additional Information 
Supporting Information 
Binding sites found with SiteMap and docking scores for compounds 1-11 in all of 
them. Selected 19 molecules based on their docking scores after induced fit simulations 
with PELE. Compounds characterization data. Enzymatic assay dose response curves 
for all compounds. LogP and LLE values for all compounds.  
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